Crinetics Pharmaceuticals (CRNX) Depreciation & Amortization (CF) (2017 - 2026)

Crinetics Pharmaceuticals' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 25.41% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $4.1 million (up 27.47% YoY), while the FY2025 annual figure was $3.9 million, up 39.68% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.2 million, up from $994000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $1.2 million in Q1 2026, with the low at $215000.0 in Q2 2022.
• The 5-year median for Depreciation & Amortization (CF) is $474000.0 (2024), against an average of $583294.1.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) fell 6.52% in 2022, then surged 200.76% in 2024.
• Crinetics Pharmaceuticals' Depreciation & Amortization (CF) stood at $280000.0 in 2022, then decreased by 6.43% to $262000.0 in 2023, then soared by 200.76% to $788000.0 in 2024, then gained by 26.14% to $994000.0 in 2025, then climbed by 16.7% to $1.2 million in 2026.
• Business Quant data shows CRNX's Depreciation & Amortization (CF) at $1.2 million in Q1 2026, $994000.0 in Q4 2025, and $1.0 million in Q3 2025.